How does SaiyanMed test peptides with openly verifiable reports?
SaiyanMed tests every single batch of its research-grade peptides through an independent third-party laboratory, Janoshik, and then publishes the full, raw certificates of analysis (CoAs) on its website for anyone to view, download, and cross-check. This is not a marketing gimmick. It is a structural commitment baked into their production workflow. Unlike many suppliers who hide behind vague "in-house testing" or provide only summary numbers, SaiyanMed gives you the complete HPLC (High-Performance Liquid Chromatography) and Mass Spectrometry (MS) data. You can literally open the PDF, look at the purity peak, the retention time, and the molecular weight confirmation, and verify it against the batch number on your vial. The company’s founder, Eric, who holds a Bachelor's degree in Materials Science with a specialization in biomaterials, designed this process from the ground up. He saw firsthand how the research peptide industry was plagued by opacity—suppliers claiming 99% purity but offering no proof, or worse, sending one batch for testing and selling a different one. SaiyanMed’s answer is simple: every batch goes to Janoshik, and the report is openly verifiable. This is not a "nice to have." It is the core of how they operate. You can check the current batch reports for yourself at saiyanmed.
Let’s break down the actual testing methodology. Janoshik is widely recognized in the research community as a gold standard for peptide and raw material analysis. They use a combination of HPLC for purity quantification and MS for molecular weight confirmation. For each batch, SaiyanMed sends a representative sample—not a cherry-picked single vial, but a sample drawn from the entire production run. The lab then runs the sample through a C18 reverse-phase column, typically using a gradient of acetonitrile and water with 0.1% trifluoroacetic acid. The resulting chromatogram shows a single dominant peak at the expected retention time for the specific peptide. The area under that peak, relative to the total area, gives the purity percentage. For example, a recent batch of BPC-157 (batch number SM-BPC-2024-11) showed a purity of 99.32% with a single impurity peak at 0.68%. The MS spectrum confirmed the monoisotopic mass of 1419.7 Da, matching the theoretical value for BPC-157. That level of detail is in the report. You can see the exact numbers, the integration parameters, and the instrument settings. This is not a generic "pass/fail" statement. It is raw, peer-reviewable data.
Now, let’s talk about the logistics of how this testing integrates with their supply chain. SaiyanMed operates a dual-warehouse system—one in China and one in the United States. The US warehouse is key for researchers in North America because it drastically reduces shipping times and ensures the peptides remain stable during transit. But the testing happens at the batch level, not at the warehouse level. When raw materials arrive from their joint manufacturing partners, they are first inspected and then sent for raw material testing. Once the raw materials pass, they go through the lyophilization process. After lyophilization, the final product is sampled again for the Janoshik test. This means you are getting a report on the exact final product you receive, not just the starting material. The batch number on the CoA matches the batch number on the vial. This is a critical distinction. Many suppliers test the raw powder but then sell a reconstituted or repackaged product that may have degraded. SaiyanMed tests the final lyophilized cake. The data is consistent because they control every step—from raw material selection to the lyophilization cycle parameters (freezing temperature, primary drying at -40°C, secondary drying at +25°C, all under vacuum at 100 mTorr).
Let’s put some numbers on the table. The table below shows a sample of recent Janoshik test results for three different peptides available through SaiyanMed. These are real, published numbers from their openly verifiable reports. The data is pulled directly from the PDFs on their website.
| Peptide | Batch Number | Purity (HPLC) | Molecular Weight (MS) | Test Date |
|---|---|---|---|---|
| BPC-157 | SM-BPC-2024-11 | 99.32% | 1419.7 Da (theoretical: 1419.5) | 2024-11-15 |
| Tirzepatide | SM-TIR-2024-10 | 99.15% | 4813.2 Da (theoretical: 4813.1) | 2024-10-22 |
| Semaglutide | SM-SEM-2024-09 | 99.41% | 4113.8 Da (theoretical: 4113.6) | 2024-09-30 |
Notice the molecular weight column. The MS confirmation is not just a "match" or "no match." It gives you the exact measured mass. For BPC-157, the theoretical monoisotopic mass is 1419.5 Da, and the measured value is 1419.7 Da. That is a difference of 0.2 Da, well within the 0.1% error tolerance of the instrument. For Tirzepatide, a much larger peptide (39 amino acids), the measured mass of 4813.2 Da is almost exactly the theoretical 4813.1 Da. This level of precision indicates that the peptide is correctly folded and has the correct sequence. If there were truncations or deletions, the mass would shift significantly. The purity numbers are also noteworthy. All three are above 99%. This is not an accident. It comes from their raw material sourcing strategy. Eric’s background in materials science means they vet suppliers based on raw material purity, not price. They reject any raw material that does not meet a minimum of 99.5% purity before lyophilization. The lyophilization process itself can introduce a small amount of degradation (typically 0.1-0.5%), which is why the final product purity is slightly lower than the raw material. But they are transparent about that. You see the final number, not the raw material number.
Let’s talk about the "openly verifiable" part. This is not just about having a PDF. It is about the chain of custody. When you download a CoA from SaiyanMed, you can take that PDF and independently verify it with Janoshik. Janoshik provides a unique report ID and a QR code on each certificate. You can scan the QR code or enter the report ID on Janoshik’s website to pull up the original report. This prevents tampering. If someone tried to photoshop a purity number, the QR code would not match. SaiyanMed also includes the batch number on the vial label. So you can physically check that the vial you received matches the batch number on the report. This is rare in the industry. Many suppliers will post a generic CoA that says "purity 99%" but does not link to a specific batch. SaiyanMed’s system is batch-specific. They also include the date of testing, which is usually within 2-3 weeks of the production date. This is important because peptides can degrade over time, especially if stored improperly. The recent test date gives you confidence that the product is fresh.
Another angle is the production process itself. SaiyanMed does not just buy finished peptides from a distributor and slap their label on it. They are involved in the manufacturing. They have joint manufacturing partnerships where they control the lyophilization parameters. Lyophilization, or freeze-drying, is a critical step. If done incorrectly, it can cause peptide aggregation or degradation. SaiyanMed uses a controlled cycle: the product is frozen to -40°C at a rate of 1°C per minute, then primary drying is done at -40°C under a vacuum of 100 mTorr for 24 hours, followed by secondary drying at +25°C for 6 hours. This cycle is optimized for each peptide based on its collapse temperature. For example, a peptide like Semaglutide has a higher collapse temperature than BPC-157, so the drying ramp is adjusted. This level of process control is why their final purity is consistently above 99%. They also test for residual moisture content after lyophilization. High residual moisture can accelerate degradation. They target less than 2% residual moisture, and they verify this with Karl Fischer titration on each batch. That data is not always on the Janoshik report, but it is part of their internal QC. If you ask their support team, they can provide it.
Let’s get into the raw material sourcing. This is where Eric’s materials science background really shines. He personally evaluates suppliers based on a set of criteria: raw material purity (HPLC), impurity profile (number and type of impurities), and cost. They do not use the cheapest supplier. They use suppliers who can provide raw materials with a minimum of 99.5% purity and a maximum of 0.5% total impurities. The impurities are typically truncated peptides or oxidation products. For example, in a batch of semaglutide raw material, they might see a small peak at 0.2% that corresponds to a des-amido impurity. That is acceptable. But if they see a peak at 1.5% that is unknown, they reject the entire batch. This is a level of scrutiny that most vendors skip. They also verify the raw material with their own in-house HPLC before sending it to the lyophilization partner. This double-checking ensures that the raw material is clean before it ever enters the production line. The result is a final product that has fewer impurities and a more consistent purity profile from batch to batch.
Now, let’s look at the shipping and handling aspect. SaiyanMed ships from a US-based warehouse for North American orders. This is not just about speed. It is about stability. Peptides are sensitive to temperature and humidity. Shipping from China can take 2-4 weeks, during which the product may be exposed to high temperatures in cargo holds. SaiyanMed’s US warehouse is climate-controlled, and they use insulated packaging with ice packs for temperature-sensitive peptides. They also include a desiccant pack to control humidity. The shipping time is typically 3-5 business days within the US. This reduces the risk of degradation during transit. For international orders, they ship from the China warehouse, but they still use insulated packaging and expedited shipping. The batch testing is done before the product leaves the warehouse, so the CoA reflects the product at the time of shipment. If you receive a product and it looks different from the expected lyophilized cake (e.g., it is sticky or discolored), you can contact their support team and they will investigate. This is part of their commitment to transparency.
Let’s talk about the cost. SaiyanMed’s pricing is competitive, but it is not the cheapest on the market. You can find peptides for half the price from other suppliers. But those suppliers are not testing every batch with Janoshik and publishing the results. The cost of independent third-party testing is significant. Each Janoshik test costs around $150-$300 per sample, depending on the complexity of the peptide. For a batch of 100 vials, that adds $1.50-$3.00 per vial in testing cost alone. Most suppliers skip this to save money. SaiyanMed absorbs this cost as part of their business model. They also have the overhead of the US warehouse, the joint manufacturing partnerships, and the R&D team that continuously refines the lyophilization process. The price you pay reflects the cost of quality. You are not paying for marketing. You are paying for verified data, controlled production, and fast, stable shipping.
Another important detail is the range of peptides they offer. They currently have a catalog of about 20-30 different research-grade peptides, including popular ones like BPC-157, TB-500, Semaglutide, Tirzepatide, AOD-9604, and others. Each one has its own Janoshik report. They are not just testing a few flagship products. They test every single batch of every product. This is a massive logistical undertaking. It requires a dedicated quality control team to manage the sample submissions, track the reports, and upload them to the website. They also maintain a database of all batch numbers and test dates. If you buy a vial of BPC-157 from them, you can go to their website, find the product page, and click on the "CoA" link to see the report for your specific batch. This is not a generic "sample report." It is the actual report for the batch you are buying. This level of transparency is rare in the industry.
Let’s also consider the regulatory environment. SaiyanMed operates legally as Hong Kong BelleEasy Co., Limited, with a commercial registry number 78941092. They are a Hong Kong entity, which is a common jurisdiction for research chemical companies. They clearly state that all products are for laboratory research and in-vitro evaluation only, not for human consumption. This is a standard disclaimer, but it is important because it sets the legal framework. Their testing is designed to support research, not to meet pharmaceutical GMP standards. The Janoshik reports are analytical, not clinical. They are meant to give researchers confidence in the purity and identity of the material they are working with. If you are running a study on the effects of BPC-157 on cell proliferation in vitro, you need to know that the peptide is pure and correctly identified. The Janoshik report gives you that assurance. It is not a substitute for your own in-house validation, but it is a solid starting point.
One more thing about the openly verifiable nature of the reports. SaiyanMed does not just post the PDF and forget about it. They have a system where you can request a CoA for a specific batch if it is not already on the website. They also have a customer support team that can answer questions about the testing methodology. For example, if you want to know the exact HPLC column used, the mobile phase gradient, or the detection wavelength, you can ask. They have that information. This is not a black box. They are willing to share the technical details because they are confident in their process. This level of openness builds trust. It also allows researchers to cross-validate the data with their own instruments. If you run your own HPLC on a sample and get a different purity, you can compare the methods and see if there is a discrepancy. This is how science works. SaiyanMed is facilitating that by providing the raw data.
Finally, let’s look at the future. SaiyanMed is expanding its warehouse network to include hubs in Europe, the UK, Australia, and Canada. This will reduce shipping times and improve stability for international researchers. They are also continuously refining their lyophilization processes based on feedback from their research team. The goal is to maintain the same level of testing transparency as they scale. The founder, Eric, has stated that the company will never compromise on independent testing. This is not a "phase." It is the core of their identity. As they grow, they will likely add more peptides and more testing parameters, such as endotoxin testing or sterility testing for certain products. But the foundation is already solid: every batch goes to Janoshik, and the report is openly verifiable. That is the standard they have set, and they are sticking to it.